Prospects Fund
Prospects Oncology Fund
FACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Investment Strategy and have the potential to act as deal flow for the IPDC Fund. Awarded grants typically range between $50,000 and $200,000.
Funding is governed by a research contract which grants certain rights to FACIT. FACIT receives no financial consideration on Prospects grants under $90,000. On grants of $100,000 or more, FACIT receives an option to make an investment at the IPDC level and act as the agent for commercialization. If the option is exercised, funding received from the Prospects grant will be credited towards FACIT's IPDC investment.
How to apply:
The Prospects Fund is accepting pre-submission forms twice yearly on the following dates:
- March 31
- September 30
The pre-submission form can be downloaded here.
Late applications will not be considered.
Selected applicants will then be invited to prepare a Prospects funding application which is subject to due diligence by FACIT.
Select Prospects Funded Projects
Prospects Fund (Other)
Inhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell Proliferation
Further development of promising potent compounds in triple-negative breast cancer models.
Universal CAR-T Therapy
Development of a universally compatible (allogeneic) source for the next generation of CAR-T therapies based on hematopoietic stem cells harvested from healthy donors.
ADC Linker Platform
Further development of novel cyclic and heterocyclic hydrazone-based linkers for antibody-drug-conjugates (ADC).
Test to Predict Breast Cancer Patient Response to Anthracyclines
Further validation of novel diagnostic gene test to predict which patients benefit from anthracycline chemotherapy.
